摘要
采用科学性、透明性和适用性的评级工具(STAR)评估并分析2022年医学期刊中发表的中国病理学指南和共识的科学性、透明性和适用性。2022年评审的病理学指南及共识共计18篇,包括指南1篇,共识17篇。评价结果显示,指南得分为21.83分,低于总体指南平均水平(43.4分);共识平均得分27.87分,与总体共识水平持平(28.3分)。得分高于总体水平的领域是“利益冲突”和“工作组”部分,得分低于总体水平的领域是“计划书”“资助”“证据”“共识方法”及“可及性”部分。综上所述,2022年病理学相关指南及共识制订欠规范,在制定过程中未提供有关临床问题推荐意见的证据检索过程、证据评价方法及分级标准,未提供达成共识的过程及方法,缺少计划书,未进行注册等。建议病理学领域指南/共识制订者重视循证医学证据,严格遵照指南制订方法与流程,进一步提升本领域指南/共识的科学性、适用性和透明性,更好地为临床工作者及患者提供支持。
The STAR tool was used to evaluate and analyze the science,transparency,and applicability of Chinese pathology guidelines and consensus published in medical journals in 2022.There were a total of 18 pathology guidelines and consensuses published in 2022,including 1 guideline and 17 consensuses.The results showed that the guideline score was 21.83 points,lower than the overall guideline average(43.4 points).Consensus ratings scored an average of 27.87 points,on par with the overall consensus level(28.3 points).Areas that scored above the overall level were"conflict of interest"and"working groups",while areas that scored below the overall level were"proposals","funding","evidence","consensus approaches"and"accessibility".To sum up,the formulation of pathology guidelines and consensuses in 2022 is not standardized,and the evidence retrieval process,evidence evaluation methods and grading criteria for recommendations on clinical issues are not provided in the formulation process;the process and method for reaching consensus are not provided,the plan is lacking,and registration is not carried out.It is therefore suggested that guidelines/consensus makers in the field of pathology should attach importance to evidence-based medical evidence,strictly follow guideline formulation methods and processes,further improve the scientific,applicable and transparent guidelines/consensuses in the field,and better provide support for clinicians and patients.
作者
师晓华
王世贤
王哲
王坚
张智弘
刘月平
张红英
高洪文
周晓燕
饶秋
梁莉
姚小红
刘东戈
梁智勇
Shi Xiaohua;Wang Shixian;Wang Zhe;Wang Jian;Zhang Zhihong;Liu Yueping;Zhang Hongying;Gao Hongwen;Zhou Xiaoyan;Rao Qiu;Liang Li;Yao Xiaohong;Liu Dongge;Liang Zhiyong(Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Editorial Office of Chinese Journal of Pathology,Chinese Medical Assocoation Publishing House,Beijing 100052,China;Department of Pathology,Basic Medical College,Air Force Medical University,Xi′an 710032,China;Department of Pathology,Fudan University Shanghai Cancer Center Department of Oncology,Shanghai Medical College,Fudan University Institute of Pathology,Fudan University,Shanghai 200032,China;Department of Pathology,Jiangsu Province People′s Hospital(the First Affiliated Hospital of Nanjing Medical University),Nanjing 210029,China;Department of Pathology,the Fourth Hospital of Hebei Medical University,Tumor Hospital of Hebei Province,Shijiazhuang 050011,China;Department of Pathology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Pathology,the Second Hospital of Jilin University,Changchun 130041,China;Department of Pathology,Jinling Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210002,China;Department of Pathology,Nanfang Hospital and Basic Medical College,Southern Medical University,Guangzhou 510515,China;Institute of Pathology and Southwest Cancer Center,Southwest Hospital,Third Military Medical University(Army Medical University),and Key Laboratory of Tumor Immunopathology,Ministry of Education of China,Chongqing 400038,China;Department of Pathology,Beijing Hospital,National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Science,Beijing 100730,China)
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2024年第6期528-534,共7页
Chinese Journal of Pathology
关键词
指南
质量控制
病理学
共识
Guideline
Quality control
Pathology
Consensus
